Aaron Coe joined the Allen Institute in 2025. As Managing Director for the Innovation Portfolio, he is responsible for cultivating relationships with scientists at the Institute across the spectrum of bioscience and technology. He is also focused on building and maintaining relationships outside the Institute that facilitate broadening our impact. This effort includes engaging investors, corporate strategic partners, and research institutions of all varieties. Aaron’s experience stems from a career at the earliest stages of company formation. Aaron has held roles in operations, finance, and business development for venture-backed companies such as Calistoga Pharmaceuticals, EpiThany, BioIntervene, and Icosavax. Aaron was instrumental in Calistoga Pharmaceutical’s sale to Gilead, whose efforts led to the approval of Zydelig, the world’s first isoform-selective PI3Kinase inhibitor.

Aaron has a degree in Linguistics and Spanish Literature from UC Santa Barbara, and an MBA from the University of Washington’s Foster School of Business. Having been an exchange student in Spain and Catalonia, Aaron speaks Spanish and Catalan. He has an affinity for acquiring languages, especially the domestically accessible ones spoken right here among the various scientific units at the Allen Institute.